Total Funding
78
60
Total FundingSeed raised
Growth Score 78 in past quarter
-17 pts
Heat Score 60 in past quarter
-10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
26358
Valink Therapeutics develops drug discovery programs focused on bispecific antibody-drug conjugates designed for complex disease biology.
- Irsyad Khairil: Co-founder & CTO
- Arne Scheu: Founder & CEO
About the Company
Valink Therapeutics researches multivalent and combinatorial target approaches intended to address treatment challenges in solid tumors and other therapeutic areas. Its work centers on identifying synergistic and less conventional target pairings and translating them into engineered biologic constructs with defined mechanisms of action. Valink
Therapeutics operates as a therapeutics development organization that integrates antibody engineering, payload selection, and linker design within a single discovery framework.